The Cancer Genome Project has identified several oncogenic mutations in BRAF that represent important opportunities for cancer drug discovery. The V600E BRAF mutation accounts for approximately 90% of the mutations identified. A strong case has emerged from molecular, cellular, and structural studies for the identification and development of inhibitors of this mutated BRAF protein. The authors have developed and run a high-throughput screen to find inhibitors of V600E BRAF using an enzyme cascade assay in which oncogenic BRAF activates MEK1, which in turn activates ERK2, which then phosphorylates the transcription factor ELK1. A phosphospecific antibody, Europium-labeled secondary antibody, and a time-resolved fluorescent readout were used to measure phosphorylation of ELK1. Overall assay variation was 12.4%. The assay was used to screen 64,000 compounds with an overall Z′ factor of 0.58 ± 0.12. A series of 3,5,di-substituted pyridines were identified as inhibitors of the cascade assay. These compounds did not inhibit a shortened activated MEK1 to ELK1 cascade but were active (0.5-27.9 µM) in a V600E BRAF assay and represent a potential starting point for future drug discovery and development. (Journal of Biomolecular Screening 2006:145-154) 
INTRODUCTION
T HE RAS TO ERK 1/2 mitogen-activated protein kinase (MAPK) signaling pathway ( Fig. 1) is activated by a variety of growth factors, hormones, and cytokines and links the extracellular environment to numerous cellular processes such as proliferation, survival, differentiation, apoptosis, and senescence. 1 Signaling through this pathway is precisely regulated by ERK1/2 substrate specificity and the duration of its activation. [2] [3] [4] The pathway is deregulated and hyperactivated in~30% of human cancers, 5 for example, by overexpression or constitutive activation of receptor tyrosine kinases or by mutations in the RAS gene family. 3, 6, 7 It is not surprising, therefore, especially given that many of the key players are enzymes with druggable active sites, that extensive attention has been paid to targeting this pathway for the development of anticancer agents. [8] [9] [10] [11] Several small molecule inhibitors that act at different levels in the RAS to ERK1/2 pathway have been described, some of which have progressed to clinical evaluation. 4, 11 The enzyme farnesyl transferase prenylates RAS proteins, facilitating their essential localization to the plasma membrane, and was one of the 1st enzymes in this pathway to be targeted therapeutically. A range of farnesyl transferase inhibitors 12 have been evaluated clinically, although their therapeutic use has proved to be disappointing. Furthermore, protein farnesyl transferase inhibitors have effects on many targets other than RAS gene family members. 13 Small molecule inhibitors of the serine-threonine kinase RAF that result in phosphorylation and activation of the downstream MAPK MEK1/ 2 include the benzamide ZM336372 14 and the pyridyl imidazole SB203580. 15 Both of these compounds unexpectedly caused activation of the target protein. The 1,3-bis-aryl-13-phenyl urea BAY 43-9006 (sorafenib), initially identified as a CRAF inhibitor, was developed following optimization of a high-throughput screening (HTS) hit 16 and is presently the subject of a phase 3 clinical trial (see below). The dual-specificity kinase MEK1/2 has also received attention as a cancer drug target, and a number of compounds with antitumor activity have been evaluated clinically. Two of the initial MEK1/2 inhibitors (again derived from HTS), PD98059 17 and UO126, 18 were found to be unsuitable for further development, although they have been widely used as laboratory tools. Subsequently, the development of another MEK1/2 inhibitor, PD184352 (C1-1040), was terminated because of metabolic instability and poor response rates in phase 2 clinical trials. 19 The more potent drug, PD0325901, which has antitumor activity against a range of tumor types and improved pharmacological properties, is currently being investigated in a clinical trial. 4 It is interesting to note that small molecule inhibitors of ERK1/2 kinase activity have not yet been described.
Taking advantage of the output of the Human Genome Project and advances in sequencing technology, the Cancer Genome Project 20 has recently identified several oncogenic mutations in BRAF 1, 22 as part of a large-scale screen for genes mutated in cancer. These mutated proteins represent significant and exciting opportunities for cancer drug discovery and development. 23 BRAF mutations occur in malignant melanomas (27%-70%), papillary thyroid (36%-53%), colorectal (5%-22%), and serous ovarian cancer (~30%). 21 Significantly, one of these mutations, the valine 599 to glutamate mutation (V599E, now redesignated V600E; see the work of Garnett and Marais 22 ), accounts for approximately 90% of the mutations identified. The V600E BRAF is 500-fold more catalytically active than the wild-type protein, 24 resulting in increased downstream signaling to ERK1/2, increased proliferation, oncogenic transformation, and tumor formation in animals. [24] [25] [26] Depletion of V600E BRAF using small interfering RNA blocks ERK1/2 activation and proliferation and induces apoptosis. 27, 28 It is also of interest that mutations in V600E BRAF rarely occur alongside mutations in RAS genes, suggesting that the mutations have a similar oncogenic effect. 25 Sorafinib inhibits V600E BRAF catalytic activity and ERK1/2 activation and has demonstrated antitumor properties against mela-noma cells with the V600E BRAF oncogenic mutation when grown as xenografts in vivo. 28 The selectivity of sorafenib for CRAF is lower than initially expected, 28, 29 and it is unclear which kinase target inhibition is primarily responsible for its observed antitumor activity. However, its activity against vascular endothelial growth factor receptor tyrosine kinases 28, 29 may explain its relatively potent antitumor activity in renal cancers. 30 Preliminary clinical responses have been disappointing in melanoma patients treated with sorafenib, although the explanation for this remains unclear. Nevertheless, the experience with this agent confirms that small molecule inhibitors of BRAF can be identified.
X-ray crystallographic studies 24 in which sorafenib was complexed with both wild-type and mutant V600E BRAF have been informative. The V600E mutation was shown to promote the active kinase conformation by disruption of the interaction between the activation segment and the glycine-rich P-loop. In fact, most of the V600E BRAF mutations occur around either the P-loop or activating segment, resulting in destabilization of the inactive enzyme conformation, thereby stimulating kinase activity.
Supported by cell biology and structural studies, the case for the identification and development of novel inhibitors of oncogenic BRAF as anticancer agents is strong, especially for agents acting on the most prevalent V600E mutant protein. With this in mind, we have developed and run a high-throughput screen using a V600E BRAF to ERK1/2 coupled enzyme cascade assay. It was reasoned that compounds identified by HTS could then be used as the basis for further development as inhibitors of the growth of tumor cells harboring the V600E BRAF mutation. Such compounds could also be active against cells with other BRAF mutations that activate the enzyme through common mechanisms. 24 The format of the screen was a coupled-enzyme cascade assay, using mutated V600E BRAF to phosphorylate and activate MEK1, resulting in phosphorylation and activation of ERK2, which then phosphorylates the ERK1/2 substrate, the transcription factor ELK1. 31 A specific phospho-ELK1 antibody and europium (Eu)labeled secondary antibody using a DELFIA ® readout was used to determine inhibition of the enzyme cascade.
MATERIALS AND METHODS
Ninety-six-well DELFIA ® strips (Perkin Elmer; cat. #1244-550) and 384-well clear enzyme-linked immunosorbent assay (ELISA) high binding plates (781061) were obtained from Greiner Bio-one (Gloucestershire, UK). Black glutathione-coated plates (Reactibind plates; cat. #15340) were from Perbio (Cramlington, Northumberland, UK). Chemicals and reagents were obtained from Sigma (Dorset, UK) unless otherwise stated. Mouse antiphospho ELK1 (ser 383; cat. #9186) and rabbit antiphospho-MEK1/2 (cat. #9121S) were purchased from Cell Signaling Technology (Beverly, MA). The secondary Eu-labeled antimouse IgG and antirabbit IgG (AD0124, AD0105) antibodies, DELFIA ® assay buffer (4002-0010), and enhancement solution (4001-0010) were purchased from Perkin Elmer Life Sciences (Cambridge, UK).
Compounds
The compound library contained a selection of diverse small molecules purchased from various commercial suppliers, including a library of kinase-directed compounds. In addition, the collection contained compounds archived in house and through Cancer Research UK.
Proteins
The V600E BRAF construct contained a full-length human BRAF cDNA with an N-terminal histidine tag, and a baculovirus was generated using the BaculoGold system (Pharmingen, San Diego, CA). The GST-p42 ERK2 (60 kDa) construct contained a full-length murine cDNA for ERK2 with a GST tag at the Nterminus. 32 The construct for GST-MEK1 (71 kDa) contained fulllength rabbit cDNA with a GST tag at the N-terminus and a Cterminal histidine tag. 32 The GST-ELK1 construct was composed of residues 307 to 428 of wild-type Elk1 with a C-terminal GST tag. 31 V600E BRAF protein was expressed in Sf9 insect cells grown in SF-900 II medium with L-glutamine (Invitrogen, Paisley, UK) following infection with the V600E BRAF baculovirus. Ninety-two hours after infection, the cells were harvested, extracted (50 mM Tris, pH 8.0, 1 mM
, 100 mM NaCl, 0.1% [v/v] Triton X-100, 1 mM phenyl methylsulfonyl fluoride [PMSF], 1 mM benzamidine, 5 µg/ml aprotinin, 5 µg/ml pepstatin, 10 µg/ml leupeptin), and centrifuged at 10,000 rpm for 10 min. The supernatant was aliquoted and stored at -80°C. The quality and quantity of the purified protein were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and coupled kinase cascade assay. [32] [33] [34] [35] A single bacterial colony expressing GST-ERK2, GST-MEK1-H6, or GST-ELK1 was used to inoculate 500 ml of Terrific broth containing 50 µg/ml carbenicillin and 10 µg/ml chloramphenicol (Sigma). After 24 h in a shaking incubator at 37°C, the culture was used to inoculate 10 flasks (~40 ml per flask) containing 500 ml of broth to give an optical density (OD) at 600 nm of~0.3. The flasks were incubated at 25°C until an OD (600 nm) of~0.6 was achieved. Protein expression was induced by the addition of 1 mM isopropyl-2-d-thiogalactopyranoside to each culture and then incubated overnight at 25°C. Cells were harvested by centrifugation at 4500g for 15 min and frozen at -20°C. Cell pellets were thawed on ice and resuspended in 25 ml cold resuspension buffer and sonicated 4× for 1 min while on ice. A 10% volume of a 10% Triton X-100 solution was added, followed by 3× centrifugation at 14,000g for 20 min. The supernatants were placed onto a prepared column with a 3 ml bed volume affinity chromatography matrix that had been prewashed with resuspension buffer. The column was washed 3 times with 20 ml wash buffer, then eluted in 20 ml of elution buffer, and 2 ml fractions collected. The protein concentration in each fraction was determined using Bradford reagent (BioRad), and the 3 most concentrated fractions were pooled. Proteins were purified by the same procedure but using different affinity chromatography matrix beads and purification buffers (see below). ERK2 and ELK1 were purified on glutathione-sepharose beads (GE Healthcare, Amersham) resuspended in phosphate-buffered saline (PBS) with 1 mM PMSF and 0.3% (v/v) β-ME and washed in 20 mM Tris (pH 7.5, 1 mM EDTA, 0.1% [v/v] Triton X-100). Protein was eluted with 50 mM Tris, pH 8.0, containing 10 mM reduced glutathione.
MEK1 was purified using nickel-agarose beads (GE Healthcare, Amersham) resuspended in 50 mM Tris, pH 8.0, containing 100 mM NaCl, 0.5 mM MgCl 2 , 0.1% (v/v) Triton X-100, 1 mM PMSF, 1 mM benzamidine, 5 µg/ml aprotinin, 5 µg/ml pepstatin, and 10 µg/ml leupeptin. The beads were washed in the same buffer but without NaCl and then in wash buffer, which included 150 mM imidazole and 0.1% (v/v) β-ME.
Pooled fractions were dialyzed overnight in 1 L dialysis buffer (20 mM Tris-Cl 7.5, 1 mM EDTA,
. The dialyzed protein was then aliquoted and stored at -20°C for ERK2 and -80°C for MEK1.
Activated MEK1 was prepared using the coupled cascade reaction with V600E BRAF and purified GST-MEK1. The reaction was initiated by the addition of V600E BRAF lysate to a dilution buffer (50 mM Tris-Cl pH 7.5, 1 mM EDTA, 100 mM NaCl, 10 mM MgCl 2 ,
mM NaF, 0.2 mM sodium orthovanadate, 1 mM PMSF, 1 mM benzamidine, 5 µg/ml aprotinin, 10 µg/ml leupeptin, 0.8 mM ATP) containing 20 µg of MEK1. This was incubated for 30 min at 30°C. The reaction was terminated by the addition of kill buffer (30 mM Tris-Cl, pH 7.5, 6 mM EDTA, 0.1% [v/v] Triton X-100, 5 mM NaF, 0.2 mM sodium orthovanadate, 0.3% [v/v] β-ME), which contained a high concentration of EDTA. The reaction mix was transferred to a prepared minicolumn with glutathione-sepharose beads. The column was washed with wash buffer (50 mM Tris-Cl pH 8.0, 100 mM NaCl, 0.1% [v/v] Triton X-100, 1 mM PMSF, 1 mM benzamidine, 5 µg/ ml aprotinin, 5 µg/ml pepstatin, 10 µg/ml leupeptin) before application of the elution buffer (50 mM Tris-Cl, pH 8.0, 40 mM reduced glutathione). A 10% volume of glycerol was added to the eluted protein, and aliquots were stored at -80°C.
Final protocol for V600E BRAF to ELK1 enzyme cascade assay
The assay buffer consisted of 50 mM Tris, pH 7.5, 10 mM MgCl 2 , 100 mM EGTA, 0.1% β-ME, 5 mM NaF, 200 µM sodium orthovanadate, and 0.5 mg/ml bovine serum albumin. The ATP, prepared daily, was dissolved in water to 1 mM and subsequently diluted to 125 µM. Staurosporine was also prepared daily in water to 1 mM and diluted to 50 µM in assay buffer. The blocking solution was PBS (PBS tablets; Oxoid, Hampshire, UK; cat.
A Screen for Oncogenic V600E BRAF Inhibitors #BR0014G), containing 5% dried milk (Marvel, Lincolnshire, UK). The final volume in the 384-well plates was 25 µl/well. All reagents were added to the well with a Multidrop dispenser (Thermo Labsystems, Hampshire, UK) unless otherwise stated.
Purified ELK1 was coated onto the plate at 2.5 µg/ml (25 µl/ well) in PBS, and the plates were incubated overnight at 4°C and washed 3 times in PBS using a Power Washer 384 (Tecan, Hampshire, UK). The plates were then blocked (50 µl/well, 5% dried milk in PBS) and incubated at room temperature for 30 min and washed as before. The master mix for the V600E BRAF-coupled enzyme cascade assay was created by mixing the proteins together in the following concentrations: V600E BRAF lysate 7.6 µl/ml, MEK1 27 µg/ml, and ERK2 270.3 µg/ml. For every 10 ml of enzyme, 7 ml of buffer was added prior to addition to the wells to give the final amounts in the well of 25 nl, 98 ng, and 120 ng for V600E BRAF, MEK1, and ERK2, respectively. During assay development, various dilutions of this enzyme mix were investigated, but the stated ratio remained constant.
Reagents were added to the plate using a Minitrak 5 (Perkin Elmer Life Sciences, Cambridge, UK). Three microliters of each compound (200 µM in 2% DMSO) was added to the central 320 wells to give a final concentration of 24 µM. This step also transferred 3 µl 2% DMSO to the outer 2 columns on each side of the plate. Seventeen microliters of enzyme master mix was added to each well except for plate columns 23 and 24, where 17 µl of assay buffer was added. Finally, 5 µl ATP at 125 µM (25 µM final concentration) was added to all wells. The positive control staurosporine (50 µM) was added manually to the first 4 wells in column A to give a final concentration of 6 µM. The plates were sealed, shaken for 1 min (IKA Shüttler MTS4, Staufen, Germany), and incubated at room temperature for 70 min. The plates were washed 3 times in 0.1% Tween 20 wash with the Power Washer 384. The primary (mouse antiphospho ELK1) and Eu-labeled secondary antibodies (125 ng/ml and 500 ng/ml, respectively) were preincubated together for a period of 30 min in DELFIA ® assay buffer. The premixed antibody solution was then added to each well (25 µl/well) using a Multidrop dispenser. The plates were sealed (adhesive cover, AB-0580; Abgene, Epsom, UK) and shaken as before, incubated at room temperature for 1.5 h, and washed again. DELFIA ® enhancement solution (35 µl/well) was added and the plates left at room temperature for 20 min before reading on a Victor 2 plate reader (Perkin Elmer Life Sciences, Cambridge, UK) using an Eu counting protocol.
Activated MEK assay
The master mix for the activated MEK1 assay was created in the same way as for the full cascade assay except that MEK1 was replaced by activated MEK1 at the same concentration. The addition of V600E BRAF lysate was replaced with an equal volume of assay buffer.
V600E

BRAF kinase assay
Assay buffer was 20 mM MOPS, pH 7.2, containing 0.5 mM EGTA, 10 mM MgCl 2 , 0.1% β-ME, and 25 mM βglycerophosphate. All incubations were at room temperature with shaking. One microgram of MEK1, 0.07 µl V600E BRAF lysate, and 0.5 µl inhibitor at the required concentrations (0.001 to 100 µM final concentration) were added to the wells of a glutathione-coated plate, and the plate was preincubated (10 min). ATP in assay buffer (10 µl), to give a final concentration of 100 µM, was added to each well, and the plates were incubated for 45 min. The plates were then washed 3 times with 200 µl 0.1% Tween 20/water. Primary antibody (rabbit antiphospho MEK1/2 diluted 1/2000) and Eulabeled antirabbit secondary antibody (diluted 1/1000) were preincubated for 30 min, and 50 µl was added to the washed plates, which were incubated for a further hour. The plates were washed as before, and 100 µl DELFIA ® enhancement solution was added. The plates were sealed and incubated for 30 min, and europium counts were measured on a Victor 2 reader.
Calculations
Percentage inhibition was calculated as follows: (100 -(S -B)/ (T -B)) × 100, where S represents the counts for each compound well, B the counts in the wells containing no enzyme, and T the counts in the total activity wells. Primary screening data were analyzed in Prism (Graphpad Software, San Diego, CA) and subsequently using OMMM/RS 3 (Accelrys, Cambridge, UK). The signal-to-noise ratio was calculated using the equation S -B/ √[(SD S) 2 + (SD B) 2 ]/2 (where SD is the standard deviation), and Z′ factors and Z factors were calculated using the method described. 36 
RESULTS
The development of a coupled enzyme assay suitable for HTS was carried out first in 96-well plates. Once appropriate conditions had been identified, the assay was transferred into 384-well plates for further optimization and screening. Previous experience with the proteins used in the cascade ( V600E BRAF lysate, MEK1, and ERK2) suggested the relative amounts of each that should be used in this assay. [33] [34] [35] The proteins were combined in this ratio (see the Materials and Methods section), and the mixture was diluted before use in individual experiments. The amount of enzyme used is shown for each experiment by referring to the volume of V600E BRAF lysate used in each well. ELK1 was used in the assay, as it is an authentic substrate for ERK1/2. 32 Figure 2 shows the relationship of the enzymatic activity through the cascade, as measured by the binding of a phospho-ELK1 antibody, to the concentration of substrate used to coat the wells of the plate. In addition, the signal was dependent on both ATP and V600E BRAF concentration ( Fig. 3) .
At this stage, the assay was further optimized in 384-well plates by simply reducing the volumes of reagents used by half ( Fig. 4) . To minimize fluctuations in temperature across the plate during the different stages of the assay and to facilitate automation, the effect of running the assay at room temperature rather than at 37°C was evaluated. Although there was some loss of signal (9.5%) following incubation at room temperature, the difference in overall assay performance was minimal.
The main disadvantage of using a nonhomogeneous ELISAbased assay format for HTS is the inclusion of several incubation steps that require time-consuming wash steps between the different stages of the assay. To facilitate later assay automation, the primary and secondary antibodies were premixed prior to addition to the plate to reduce the number of incubation/wash steps. Rather than compromising the assay signal, premixing the antibodies appeared to result in a 1.5-to 2-fold increase in the signal without changing background counts (Fig. 5) .
The effect of DMSO on the assay signal was also investigated. Higher concentrations of DMSO (>2%) had detrimental effects on the Eu counts, but at the concentrations of DMSO present in the screen (0.24%) and in the determination of compound potency (1.2%), the loss of signal was minimal. Also, any effect of DMSO would be accounted for in the total activity wells on each plate, which had an equivalent amount of DMSO present to that in the compound wells.
Using optimized conditions, and to ensure linearity of response, a time-course experiment was carried out (Fig. 6) . The enzymatic activity through the coupled enzyme cascade was linear up to 100 min for 2 concentrations of enzyme mix (25 nl and 12.5 nl V600E BRAF). An incubation time of 70 min was selected for later screening assays, as this time point was within the linear range and 
Compound screening
Approximately 64,000 compounds in 17 batches were screened using the final protocol described in the Materials and Methods section. Taking all batches into account, the overall signal-to-background ratio was 60, the signal-to-noise ratio was 9.6, and the mean Z′ and Z factors that were used to judge assay performance on each plate were 0.58 ± 0.12 and 0.47 ± 0.18, respectively. Figure 7 illustrates the assay performance from 1 batch of 14 plates. The data from all plates in this batch were considered acceptable. Twelve plates had Z′ factors greater than 0.5, and all plates had Z′ factors greater than 0.4. The overall performance of the screen was also considered acceptable, and Figure 8 shows the mean Z′ factor for each batch of plates in the whole screen. Plates were retested if the Z′ factor was <0.4 or, as occurred in 2 batches, variation in the compound wells was high, resulting in unsatisfactory Z factors as seen in batches 4 and 7 (Fig. 8) .
For the primary screen, compounds were selected as hits if they gave a percentage inhibition greater than 3 standard deviations from the mean percentage inhibition of all compounds on the plate. 37 Figure 9 shows an example of the screening results from 640 compounds and the identification of the hits on these 2 plates. From the primary screen, a total of 496 unconfirmed hits were identified (0.7% hit rate). The activity of these compounds was subsequently determined in duplicate in the same assay format. For this confirmation screen, compounds that inhibited the activity of the coupled-enzyme cascade by more than 50% at a concentration of 24 µM were selected. The activity of 21 compounds was confirmed in this assay (0.03%). Within this collection of hits, there were 3 clusters of structurally related compounds, containing 11, 3, and 2 compounds, respectively, whereas the other hits were singletons. The properties of the largest cluster of hits were investigated further.
3,5,di-substituted pyridines are V600E BRAF inhibitors
The activity of the largest cluster of hits, a series of 3-(3′hydroxybenzylamino) 5 pyridines, is shown in Table 1 together with their chemical structures. The IC 50 of the compounds in the cascade assay ranged from 0.8 µM to more than 50 µM. Enzyme inhibition curves for 2 compounds are shown in Figure 10 . None of the compounds in this series of pyridines were active in the truncated cascade assay (Z′ factor of 0.8 and Z factor of 0.6), which included activated MEK1 in place of the unactivated protein used in the primary cascade assay, and it was therefore concluded that the activity seen in the full cascade was due to inhibition of V600E BRAF. The activity of the compounds was then determined in a V600E BRAF kinase assay in which MEK1 was phosphorylated by V600E BRAF. All the compounds were active in this assay ( Table 1) with a 75-fold range of potencies (IC 50 = 0.5-37.9 µM).
DISCUSSION
V600E
BRAF is an attractive cancer drug target, and inhibitors of this mutated enzyme should play a role in the treatment of cancer and malignant melanoma in particular. Kinases in general have proved to be highly druggable targets, and HTS has played a key role in the discovery of several kinase inhibitors. 38 There are various assay options available for kinase assays suitable for HTS that include both isotopic and nonisotopic end points. [38] [39] [40] Several different assay formats were initially investigated for this screen, including the use of myelin basic protein-coated FlashPlates ® , Alphascreen ™ (Perkin Elmer Life Sciences), and a DELFIA ® assay based on the use of glutathione-coated plates to bind phosphorylated GST tagged ELK1. A DELFIA ® format that uses substrate coated onto the wells of a microplate appeared to give the most robust assay for further optimization and automation. This assay relies on the sequential phosphorylation and activation of proteins in a cascade from mutated V600E BRAF to MEK1, to ERK2, and finally to ELK1. Previously, this assay format has been employed successfully with a radiometric end point 14, 17, 40, 41 and using a DELFIA ® end point, 42 but it has not been reported before using V600E BRAF and ELK1 in the cascade. The inclusion of a time-resolved fluorescent end point to measure phosphorylation of the final substrate in the cascade provides an alternative and sensitive nonisotopic end point that has proved suitable for HTS. [38] [39] [40] 44 In general, low concentrations of ATP near or below the enzyme Km tend to favor the identification of ATP-competitive inhibitors of the enzyme. However, in practice, conditions are adjusted to obtain a robust and reproducibly measurable signal window consistent with economic use of reagents. The concentration of ATP is an important consideration in kinase assays. For the coupled cascade assay used here, a precise Km determination would require individual measurements of the Km for each enzyme, and in a coupled assay, different rates of reaction may affect the overall Km. The concentration of ATP that resulted in maximum signal was approximately 100 µM (Fig. 2) . A concentration of 25 µM was selected, which represented approximately 25% of maximal activity but also showed a good signal above background.
Following the transfer of the assay from 96-well plates to 384well plates, final assay conditions were determined. Reducing the number of wash steps in the assay by premixing the primary and secondary antibodies and using room temperature for all incubation steps facilitated automation and helped to overcome the practical disadvantages of this ELISA-based assay format. The automated assay was used to screen a diverse collection of compounds with acceptable performance criteria. However, a small number of batches of plates did not pass the acceptance criteria (Z′ > 0.4) or had generally poor reproducibility across the compound wells, resulting in very low Z factors as shown in Figure 8 . These plates were subsequently retested satisfactorily. Where poor performance necessitated retests, this was largely attributed to the wash steps required in the assay, although other systematic errors as well as the complex nature of the assay could have contributed to the overall variation observed. Although a relatively large number of hits were identified in the primary screen, the confirmation rate was low, and the same factors may also provide an explanation for the low confirmation rate for the cherry-picked hits. In addition, the criteria for selection in the retest assay were more stringent (>50% inhibition) than used to identify hit compounds in the primary screen (>3 SD from mean of all compounds). In approximately 40% of the plates from which hits were cherry-picked, the activity represented by a 3-SD cutoff was equivalent to less than 40% enzymatic inhibition, and on some plates, this was as low as 25% enzyme inhibition. Thus, many of the hits identified in the primary screen would not have been confirmed using the more stringent >50% inhibition criterion. Nevertheless, a number of compounds were identified as confirmed hits, including a large cluster of 3,5,di-substituted pyridines.
It was important to determine at which point in the cascade inhibitors were acting. This was achieved by using an assay in which V600E BRAF enzyme was not present, the shortened cascade being initiated with activated MEK1. Subsequently, the compounds were assayed in a V600E BRAF kinase assay using MEK1 as the substrate. Interestingly, none of the hits identified in the screen were active in the activated MEK1 assay, and all the compounds in the cluster were active in the V600E BRAF to MEK1 assay. Thus, all of the hits showed activity against V600E BRAF but not against MEK1. The rank order of the compounds in the primary cascade assay and the V600E BRAF kinase assay, the end point of which was phosphorylation of MEK1, was not the same, and this may be partially explained by the different ATP concentrations used (25 µM and 100 µM, respectively). There may also be differences in the ATP competitiveness of the compounds, even though they belong to 1 chemically related series. It is conceivable that the compounds are acting as inhibitors of MEK phosphorylation in a manner simi- Table 1 . A B lar to that previously described. 4 As the compound series is progressed, the precise mechanism by which these compounds inhibit the activity of V600E BRAF will be elucidated in assays to determine ATP competitiveness, inhibition of phosphorylation of V600E BRAF peptide substrates rather than MEK1 itself, and by using x-ray crystallographic information, as has been used previously for sorafinib. 24 Both cascade screens 14, 17, [40] [41] [42] and specific kinase assays 16 have been used previously to find inhibitors of the mapkinase pathway. We chose to use a cascade assay, despite its obviously increased complexity, for HTS mainly because it gave us the opportunity of identifying inhibitors of other members of the enzyme cascade. In our screen, we identified only inhibitors of V600E BRAF, and this may be a feature of this type of assay or to the relatively small number of compounds screened. The outcome of the screen may have been different if we had screened a larger or different set of compounds. Using a similar CRAF to ERK2 cascade assay in SPA format 42 to screen 335,000 compounds, a hit rate of approximately 0.4% (at greater than 60% inhibition) was reported, although it is not clear whether this is a confirmed hit rate. It is interesting that in this previous screen, at least 1 MEK inhibitor as well as 1 CRAF inhibitor were identified, illustrating that it is possible to find inhibitors of more than 1 enzyme in a cascade assay. It is also of interest that as in our screen, no inhibitors of ERK2 were identified.
In summary, a high-throughput screen to find inhibitors of the kinase activity of oncogenic mutated V600E BRAF has been developed. The assay was based on a coupled enzyme cascade format using V600E BRAF lysate to initiate activity through MEK1 and ERK2. Phosphorylation of the authentic ERK1/2 substrate, ELK1, was determined using a phospho-specific antibody and a timeresolved fluorescently labeled secondary antibody. Despite its complexity, the assay was acceptably robust under automated conditions. A screen of approximately 64,000 compounds identified a number of hits. These were active in the V600E BRAF to ELK1 cascade but not the activated MEK1 to ELK1 assay, showing that they acted on BRAF but not MEK1 or ERK2. A series of 3,5,disubstituted pyridines were shown to inhibit V600E BRAF kinase assay, and this series represents an interesting potential starting point for future medicinal chemistry exploration and further drug discovery.
